Life sciences developer and operator IQHQ is facing increasing financial challenges as its creditors place additional pressures on the San Diego-based company in a tough lab leasing environment.
Six registered funds with $707M allocated to IQHQ marked down their positions in the second half of 2025, an indicator of sliding values for the many lab megadevelopments launched in a frenzy in 2022 and 2023.
IQHQ, one of the largest privately held lab developers in the country, with an operational portfolio of 3.6M SF, has secured investments from some major names, including Bluerock and T. Rowe Price, and in January 2025 landed $900M in rescue financing from a…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
